Sell­ing shares at a dis­count, Zymeworks grabs $100M cash in hopes of turn­around

Biotech vet­er­an Ken­neth Gal­braith got the cash he wants to right the ship at Zymeworks — but not with­out some com­pro­mis­es.

The Van­cou­ver-based com­pa­ny re­vealed late …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER